|
PET-directed chemoradiation (CRT) with induction FOLFOX compared to induction carboplatin/paclitaxel (CP) in patients with locally advanced esophageal adenocarcinoma (EA). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical |
|
|
Stock and Other Ownership Interests - LumaCyte |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo; Jounce Therapeutics; Lilly; Merck; Merck Serono; Michael J. Hennessy Associates; Ono Pharmaceutical; Pfizer; Rgenix |
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche |
|
|
Stock and Other Ownership Interests - Calithera Biosciences |
Honoraria - Clinical Care Options; MedEd; RMEI Medical Education |
Consulting or Advisory Role - Health Advances |
Research Funding - Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
Research Funding - Genelux (Inst); Genentech (Inst) |
Travel, Accommodations, Expenses - Intuitive Surgical |
Other Relationship - NIH/Coordinating Center for Clinical Trials |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; MORE Health |
Research Funding - CivaTech Oncology |
Travel, Accommodations, Expenses - Alpha Tau; CivaTech Oncology |
|
|
Consulting or Advisory Role - AstraZeneca; Diffusion Pharmaceuticals; Merck |
|
|
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Pieris Pharmaceuticals |
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Zymeworks |
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Pieris Pharmaceuticals |
|
|
No Relationships to Disclose |